Extended Anticoagulation Therapy With Rivaroxaban for Cancer‐Associated Low‐Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.045541 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Wei Xiong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine Xinhua Hospital, Shanghai Jiaotong University School of Medicine Shanghai China. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Neoplasms, Pulmonary Embolism, Rivaroxaban. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The ONCO PE (Optimal Duration of Anticoagulation Therapy for Low‐Risk Pulmonary Embolism Patients With Cancer) trial demonstrated the superiority of 18‐month compared with 6‐month rivaroxaban treatment for cancer‐associated low‐risk pulmonary embolism in reducing recurrent venous thromboembolism. However, it was uncertain whether the results could be applicable to patients with different performance status (PS) scores, which evaluate the physical condition of patients with cancer undergoing anticancer treatment.
Methods
In this post hoc subgroup analysis of the ONCO PE trial, we compared the 18‐month and 6‐month rivaroxaban treatment groups in 2 subgroups: the low PS score (no restricted physical activity: PS=0; n=79) and high PS score (restricted physical activity: PS ≥1; n=99) subgroups. The primary end point was recurrent venous thromboembolism, and the major secondary end point was major bleeding.
Results
The rate of recurrent venous thromboembolism was lower in the 18‐month rivaroxaban group than in the 6‐month rivaroxaban group, significantly among the low PS score subgroup (2.7% versus 19.0%, P =0.049) and numerically among the high PS score subgroup without statistical significance (7.7% versus 19.1%, P =0.10). The rate of major bleeding was not different between the 2 groups among the low PS score subgroup (2.7% versus 7.1%, P =0.39), while it was numerically higher in the 18‐month rivaroxaban group than in the 6‐month rivaroxaban group among the high PS score subgroup, without statistical significance (11.5% versus 4.3%, P =0.20).
Conclusions
Extended anticoagulation therapy for patients with cancer‐associated low‐risk pulmonary embolism might have a potential benefit in reducing thrombotic risk irrespective of PS score, whereas there might be some concerns on an increased risk of major bleeding in patients with a high PS score. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04724460.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine Xinhua Hospital, Shanghai Jiaotong University School of Medicine Shanghai China.
- Department of Cardiovascular Medicine Graduate School of Medicine, Kyoto University Kyoto Japan.
- Department of Data Science Hyogo Medical University Nishinomiya Japan.
- Division of Cardiology Shizuoka Cancer Center Shizuoka Japan.
- Department of Cardiovascular Medicine Shiga University of Medical Science Otsu Shiga Japan.
- Department of Cardiovascular Medicine Kurashiki Central Hospital Kurashiki Japan.
ORCID-Profile: Wei Xiong, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Wataru Shioyama, Yoshihisa Nakagawa, Ryuki Chatani, Tatsuhiro Shibata, Nagisa Morikawa, Yoshihiro Fukumoto, Yuji Nishimoto, Koh Ono, Takeshi Kimura
Zitieren
APA
Xiong, W., Yamashita, Y., Morimoto, T., Muraoka, N., Shioyama, W., Nakagawa, Y., Chatani, R., Yamamoto, H., Shibata, T., Morikawa, N., Fukumoto, Y., Nishimoto, Y., Ono, K., Kimura, T., & ONCO PE Trial Investigators (2026). Extended Anticoagulation Therapy With Rivaroxaban for Cancer‐Associated Low‐Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.045541
Vancouver
Xiong W, Yamashita Y, Morimoto T, Muraoka N, Shioyama W, Nakagawa Y, et al. Extended Anticoagulation Therapy With Rivaroxaban for Cancer‐Associated Low‐Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.045541
BibTeX
@article{Xiong2026,
author = {Xiong, Wei and Yamashita, Yugo and Morimoto, Takeshi and Muraoka, Nao and Shioyama, Wataru and Nakagawa, Yoshihisa and Chatani, Ryuki and Yamamoto, Hiromi and Shibata, Tatsuhiro and Morikawa, Nagisa and Fukumoto, Yoshihiro and Nishimoto, Yuji and Ono, Koh and Kimura, Takeshi and ONCO PE Trial Investigators, ONCO PE Trial Investigators},
title = {Extended Anticoagulation Therapy With Rivaroxaban for Cancer‐Associated Low‐Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.045541}
}
EUVIMED